In the treatment of GBM, most of the molecular targets studied in recent years involve kinases, and in particular PI3K, PDK1, CK2, c-Src, Akt/PKB, FAK, VEFRG, and EGFR. This evidence concerns the gene TSPO and glioblastoma.